KINAXO Biotechnologies GmbH announced today that the European Patent Office has granted a patent entitled "Proteome-wide quantification of small molecule binding to cellular target proteins" (EP2045332B1). The patent covers technologies exclusively marketed by KINAXO under the trademarks Cellular Target Profiling^®, KinAffinity^® and Epigenetics Target Profiling^TM. Patent applications in the United States and Japan are pending.

KINAXO combines state-of-the-art chemical proteomics methods with the latest quantitative mass spectrometry techniques to profile small molecules in cell or tissue extracts. Profiling is performed against endogenously expressed proteins in the presence of cellular co-factors and native complex partners. This distinguishes KINAXO's profiling technologies from traditional biochemical assays using recombinant proteins.

Cellular Target Profiling^® enables comprehensive selectivity analysis and prediction of off-target liabilities for compounds with an unclear target spectrum. KinAffinity^®, and Epigenetics Target Profiling^TM deliver high quality, native selectivity data for kinase inhibitors or epigenetic drugs.

"The granted patent emphasizes our leadership in providing chemical proteomics solutions for research and development. KINAXO's extensive experience and world-class expertise deliver powerful insights into cellular small molecule target interactions. Such knowledge significantly supports decision-making at various stages of the drug development process" says Henrik Daub, KINAXO's CTO and main inventor of the patent. 

About KINAXO - http://www.kinaxo.com/
KINAXO Biotechnologies GmbH, based in Munich/Martinsried, supports pharma­ceutical companies in developing targeted drugs. Our services include drug mode-of-action analysis, cellular target profiling, target deconvolution, and biomarker discovery.

On February 9, 2011 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in KINAXO Biotechnologies GmbH. Within Evotec, KINAXO will become a center of excellence for mass spectrometry-based chemical proteomics and phosphoproteomics technologies. The acquisition confirms Evotec's leading position as a fully integrated drug discovery and early development partner for pharmaceutical and biotechnology companies.